A synthetic Novo Nordisk's PYY analogue, PYY1875/NNC0165‐1875 (NN9775‐4708), was examined in combination with semaglutide for obesity treatment but was recently discontinued following the completion of Phase II trials.156, 157. The gene discussed is PYY; the disease is obesity disorder.